Monographie - Carfilzomib

Carfilzomib

Chemical structure

Tradename

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Kyprolis

Belgium, Germany, Great Britain, Mexico, Romania, Spain, Switzerland, United States of America

References : Carfilzomib

	Type	Publication
3348	Manufacturer	Carfilzomib (Kyprolis®) - Résumé des caractéristiques du produit Amgen 2016
3986	Journal	Kim S, Krämer I. Physikalisch-chemische Stabilität von Carfilzomib (Kyprolis®) im Originalbehältnis nach Erstanbruch und in applikationsfertigen Zubereitungen. Krankenhauspharmazie 2017 ;38:377-82.
4045	Journal	Sestak V, Roh J, Klepalova L, Kovarikova P. A UHPLC-UV-QTOF study on the stability of carfilzomib, a novel proteasome inhibitor. J Pharm Biomed Anal 2016 ;124:365-373
4047	Journal	Kim S.H, Krämer I. Physicochemical stability of carfilzomib (Kyprolis®) containing solutions in glass vials, ready-to-administer plastic syringes and infusion bags over a 28-day storage period. J Oncol Pharm Practice 2017 ;25,2: 339-350